- Home
- SSSS vs IMUX Comparison
SSSS vs IMUX Comparison
Compare SSSS & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- IMUX
- Stock Information
- Founded
- SSSS 2010
- IMUX 2016
- Country
- SSSS United States
- IMUX United States
- Employees
- SSSS N/A
- IMUX N/A
- Industry
- SSSS Finance: Consumer Services
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- SSSS Finance
- IMUX Health Care
- Exchange
- SSSS Nasdaq
- IMUX Nasdaq
- Market Cap
- SSSS 118.1M
- IMUX 110.8M
- IPO Year
- SSSS N/A
- IMUX N/A
- Fundamental
- Price
- SSSS $4.91
- IMUX $1.11
- Analyst Decision
- SSSS Buy
- IMUX Strong Buy
- Analyst Count
- SSSS 2
- IMUX 5
- Target Price
- SSSS $6.00
- IMUX $13.20
- AVG Volume (30 Days)
- SSSS 177.4K
- IMUX 931.7K
- Earning Date
- SSSS 11-07-2024
- IMUX 11-07-2024
- Dividend Yield
- SSSS N/A
- IMUX N/A
- EPS Growth
- SSSS N/A
- IMUX N/A
- EPS
- SSSS N/A
- IMUX N/A
- Revenue
- SSSS $5,903,895.00
- IMUX N/A
- Revenue This Year
- SSSS N/A
- IMUX N/A
- Revenue Next Year
- SSSS $6.05
- IMUX N/A
- P/E Ratio
- SSSS N/A
- IMUX N/A
- Revenue Growth
- SSSS 5.43
- IMUX N/A
- 52 Week Low
- SSSS $3.32
- IMUX $0.97
- 52 Week High
- SSSS $5.44
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- SSSS 53.68
- IMUX 36.96
- Support Level
- SSSS $4.81
- IMUX $1.02
- Resistance Level
- SSSS $5.44
- IMUX $1.28
- Average True Range (ATR)
- SSSS 0.27
- IMUX 0.08
- MACD
- SSSS -0.03
- IMUX -0.00
- Stochastic Oscillator
- SSSS 41.11
- IMUX 35.29
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.